Viewpoints

The industry’s M&A activity is on the up and expected to continue to rise in 2024.

Clarivate has released its 2024 Drugs to Watch report, highlighting 13 therapies with great potential.

Drug shortages across Europe are being exacerbated by increased demand, struggling supply chains, and manufacturer suspensions.

The report indicates a rise in biotech funding and subsequent growth for pharma contract services.

European vaccine manufacturing is being boosted with high level investments.

Only a significant joint effort across the supply chain will help to make healthcare more sustainable and reduce the impact of climate change on global health.

Start-ups are plagued with common issues that dramatically decrease their odds of achieving investor funding.

The UK and EU have negotiated a new draft deal for Britain to re-join the Horizon Europe research programme.

The debate surrounding drug pricing changes rages on.

BIO is a powerful business development conference that can help make a lot of deals become reality.

Despite being a relatively small nation, Switzerland is booming for biotech innovation.

Strike action is impacting numerous sectors across Europe, including the bio/pharma industry.

A further setback to the publication of the pharmaceutical legislative changes in Europe may mean time is running out for appropriate review before 2024 parliamentary elections.

The bio/pharma outsourcing industry continues to be integral in the development and manufacture of medicines.

Soaring energy costs are compounding the challenges currently being faced by the European bio/pharma industry.

Although some headway is being made into more gender-diverse executive levels in pharma, much more work is still needed.

The latest report from Clarivate has been published, highlighting 15 potential blockbusters to watch out for in 2023, the majority of which are personalized medicines.

Anti-obesity drugs have the potential to be the next blockbusters, according to market analysis.

Industry and the government must work closely to ensure the UK remains a competitor in the clinical research field.

Pharmaceutical Technology Europe pays tribute to the role Her Majesty Queen Elizabeth II had in promoting innovation within life sciences.

As winter approaches, the next generation of COVID-19 vaccines are being prepared and scheduled, ready for distribution across Europe and the world.

Guest contributor B.S. Sathya Durga discusses the importance of modernizing India's pharmaceutical manufacturing industry.

GSK has completed its demerger of Haleon and has signed an agreement to help support future pandemic preparedness in Europe.

Guest contributor Frederic Kahn discusses the state of the Indian pharmaceutical manufacturing industry.

Dame Deborah James’ legacy and the millions raised through her campaigning will undoubtedly be a big boost to clinical research, ultimately providing new and promising treatments for bowel cancer patients.

Cases of monkeypox are rising around the world, but it is unlikely the virus will become a pandemic problem.

A long-running criminal case involving the theft of confidential data from a pharma giant is still unravelling, as more convictions are made.

The AMR Action Fund has made its first investments, marking an important step forward for the partnership to achieve its goal of bringing new treatments to the market for priority pathogens.

Researchers from the Telomere-to-Telomere Consortium have discovered new properties about junk DNA that could have wide-reaching implications.

What if we are underestimating China’s response to US/EU inshoring?